Biological and clinical relevance of stem cells in pancreatic adenocarcinoma

Zeshaan A. Rasheed, William Matsui

Research output: Contribution to journalArticle

Abstract

Cancer stem cells (CSC) have been identified in a growing number of human malignancies. CSC are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting, and a growing number of studies have shown that they display other functional characteristics, such as invasion and drug resistance. These unique functional properties implicate a role for CSC in clinical consequences, such as initial tumor formation, relapse following treatment, metastasis, and resistance, suggesting they are a major factor in directing clinical outcomes. Pancreatic adenocarcinoma is a highly-aggressive disease with a propensity for early metastasis and drug resistance. Tumorigenic pancreatic cancer cells have been identified using the cell surface antigens CD44, CD24, and CD133, as well as the high expression of aldehyde dehydrogenase (ALDH). In vitro and in vivo studies have shown that ALDH- and CD133-expressing pancreatic CSC have a greater propensity for metastasis, and ALDH-expressing CSC have been shown to be resistant to conventional chemotherapy. In clinical samples from patients with resected pancreatic adenocarcinoma, the presence of ALDH-expressing CSC was associated with worse overall survival. The development of CSC-targeting therapies might be important in changing the clinical outcomes of patients with this disease, and others and we have begun to identify novel compounds that block CSC function. This review will discuss the biological and clinical relevance of CSC in pancreatic cancer, and will discuss novel therapeutic strategies to target them.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume27
Issue numberSUPPL.2
DOIs
StatePublished - 2012

Fingerprint

Neoplastic Stem Cells
Adenocarcinoma
Stem Cells
Aldehyde Dehydrogenase
Pancreatic Neoplasms
Neoplasm Metastasis
Drug Resistance
Neoplasms
Surface Antigens
Cell- and Tissue-Based Therapy
Recurrence
Drug Therapy
Survival

Keywords

  • Cancer stem cell
  • Drug resistance
  • Metastasis
  • Pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. / Rasheed, Zeshaan A.; Matsui, William.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 27, No. SUPPL.2, 2012, p. 15-18.

Research output: Contribution to journalArticle

Rasheed, Zeshaan A. ; Matsui, William. / Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. In: Journal of Gastroenterology and Hepatology (Australia). 2012 ; Vol. 27, No. SUPPL.2. pp. 15-18.
@article{abe71796c8464476b6d32a7287f512e5,
title = "Biological and clinical relevance of stem cells in pancreatic adenocarcinoma",
abstract = "Cancer stem cells (CSC) have been identified in a growing number of human malignancies. CSC are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting, and a growing number of studies have shown that they display other functional characteristics, such as invasion and drug resistance. These unique functional properties implicate a role for CSC in clinical consequences, such as initial tumor formation, relapse following treatment, metastasis, and resistance, suggesting they are a major factor in directing clinical outcomes. Pancreatic adenocarcinoma is a highly-aggressive disease with a propensity for early metastasis and drug resistance. Tumorigenic pancreatic cancer cells have been identified using the cell surface antigens CD44, CD24, and CD133, as well as the high expression of aldehyde dehydrogenase (ALDH). In vitro and in vivo studies have shown that ALDH- and CD133-expressing pancreatic CSC have a greater propensity for metastasis, and ALDH-expressing CSC have been shown to be resistant to conventional chemotherapy. In clinical samples from patients with resected pancreatic adenocarcinoma, the presence of ALDH-expressing CSC was associated with worse overall survival. The development of CSC-targeting therapies might be important in changing the clinical outcomes of patients with this disease, and others and we have begun to identify novel compounds that block CSC function. This review will discuss the biological and clinical relevance of CSC in pancreatic cancer, and will discuss novel therapeutic strategies to target them.",
keywords = "Cancer stem cell, Drug resistance, Metastasis, Pancreatic cancer",
author = "Rasheed, {Zeshaan A.} and William Matsui",
year = "2012",
doi = "10.1111/j.1440-1746.2011.07015.x",
language = "English (US)",
volume = "27",
pages = "15--18",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "SUPPL.2",

}

TY - JOUR

T1 - Biological and clinical relevance of stem cells in pancreatic adenocarcinoma

AU - Rasheed, Zeshaan A.

AU - Matsui, William

PY - 2012

Y1 - 2012

N2 - Cancer stem cells (CSC) have been identified in a growing number of human malignancies. CSC are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting, and a growing number of studies have shown that they display other functional characteristics, such as invasion and drug resistance. These unique functional properties implicate a role for CSC in clinical consequences, such as initial tumor formation, relapse following treatment, metastasis, and resistance, suggesting they are a major factor in directing clinical outcomes. Pancreatic adenocarcinoma is a highly-aggressive disease with a propensity for early metastasis and drug resistance. Tumorigenic pancreatic cancer cells have been identified using the cell surface antigens CD44, CD24, and CD133, as well as the high expression of aldehyde dehydrogenase (ALDH). In vitro and in vivo studies have shown that ALDH- and CD133-expressing pancreatic CSC have a greater propensity for metastasis, and ALDH-expressing CSC have been shown to be resistant to conventional chemotherapy. In clinical samples from patients with resected pancreatic adenocarcinoma, the presence of ALDH-expressing CSC was associated with worse overall survival. The development of CSC-targeting therapies might be important in changing the clinical outcomes of patients with this disease, and others and we have begun to identify novel compounds that block CSC function. This review will discuss the biological and clinical relevance of CSC in pancreatic cancer, and will discuss novel therapeutic strategies to target them.

AB - Cancer stem cells (CSC) have been identified in a growing number of human malignancies. CSC are functionally defined by their ability to self-renew and recapitulate tumors in the ectopic setting, and a growing number of studies have shown that they display other functional characteristics, such as invasion and drug resistance. These unique functional properties implicate a role for CSC in clinical consequences, such as initial tumor formation, relapse following treatment, metastasis, and resistance, suggesting they are a major factor in directing clinical outcomes. Pancreatic adenocarcinoma is a highly-aggressive disease with a propensity for early metastasis and drug resistance. Tumorigenic pancreatic cancer cells have been identified using the cell surface antigens CD44, CD24, and CD133, as well as the high expression of aldehyde dehydrogenase (ALDH). In vitro and in vivo studies have shown that ALDH- and CD133-expressing pancreatic CSC have a greater propensity for metastasis, and ALDH-expressing CSC have been shown to be resistant to conventional chemotherapy. In clinical samples from patients with resected pancreatic adenocarcinoma, the presence of ALDH-expressing CSC was associated with worse overall survival. The development of CSC-targeting therapies might be important in changing the clinical outcomes of patients with this disease, and others and we have begun to identify novel compounds that block CSC function. This review will discuss the biological and clinical relevance of CSC in pancreatic cancer, and will discuss novel therapeutic strategies to target them.

KW - Cancer stem cell

KW - Drug resistance

KW - Metastasis

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84856967625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856967625&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2011.07015.x

DO - 10.1111/j.1440-1746.2011.07015.x

M3 - Article

C2 - 22320910

AN - SCOPUS:84856967625

VL - 27

SP - 15

EP - 18

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - SUPPL.2

ER -